SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vector1 who wrote (5960)11/17/1998 12:32:00 AM
From: aknahow   of 9719
 
The short answer is, yes. The long answer, is a question. Does anyone know if it is common for any of the FDA panelist to have the specific disease a drug is designed to treat? While shareholders might think that was great, it would seem to introduce bias into the review process. If I had a specific disease why would anyone think I would not see the data presented from my own very special personal perspective? Most of us can do that without any disease. I do assume that the FDA is not adding people to a panel that do not have a scientific or medical background, but rather just as representatives of of a particular illness. But, I can see where a certain line of thinking might insist an activist for any specific disease must be included in the review process even lacking the other standard qualifications. Tell me this is not so!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News